This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pagibaximab

Biosynexus Incorporated

Drug Names(s): BSYX-A110

Description: BSYX-A110 is a monoclonal antibody that binds to all types of Staphylococci bacteria, as well as enterococci and group A streptococci.

Deal Structure: Biosynexus and Sunol (Altor)
In 2000, Sunol licensed certain technologies and products for anti-staphylococcal antibodies to Biosynexus. In return, Sunol obtained an equity position in Biosynexus and royalty rights on the future sale of Biosynexus' products.

The license and equity interest were assigned to Altor as part of its spin-off from Sunol in 2002.

In 2005, Altor sold its equity holding in Biosynexus to QVT, a New York-based hedge fund, but retained its licensing interest and royalty rights in Biosynexus' products.

GSK, Medimmune, and Biosynexus
In October 2002, GlaxoSmithKline Biologicals and Biosynexus announced that they have entered into an exclusive collaborative agreement to develop and commercialize staphylococcal antibodies and vaccines to prevent and treat infections caused by staphylococcal bacteria. BSYX-A110 is included in the agreement.

The agreement calls for the parties to co-develop BSYX-A110 monoclonal antibodies currently in...See full deal structure in Biomedtracker

Partners: Altor BioScience Corporation


Pagibaximab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug